VIR-2986
Chronic Hepatitis Delta (CHD)
Phase 1Active
Key Facts
About Vir Biotechnology
Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.
View full company profileTherapeutic Areas
Other Chronic Hepatitis Delta (CHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tocilizumab | Vir Biotechnology | Phase 3 |